Chapter: 1 INTRODUCTION

1.1 Report Description
1.2 Key Market Benefits
1.3 Key Market Segments
1.4 Research Methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO Perspective
2.2 Market Beyond What to Expect by 2025 ($million)

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

Chapter: 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Key Findings

3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies

3.3 Government Regulation
3.4 Reimbursement Scenario
3.5 Porter's Five Force Analysis

3.5.1 Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
3.5.2 Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
3.5.3 High capital investment and patent provision lowers the threats from new entrants
3.5.4 Difficulty to imitate the original biologics lowers the threat of substitutes
3.5.5 Industry rivalry is low to moderate due to presence of few competitors

3.6 Value Chain Analysis

3.7 Market Share Analysis, 2014

3.8 Market Dynamics

3.8.1 Drivers

3.8.1.1 Rising incidences of autoimmnue and respiratory conditions:
3.8.1.2 New Drugs in Pipeline
3.8.1.3 Increasing adoption rate of anti-inflammatory drugs

3.8.2 Restraints

3.8.2.1 Side effects of anti-inflammtory drugs
3.8.2.2 Patenet expiries

3.8.3 Opportunities

3.8.3.1 Developing biosimilars for the existing drugs
3.8.3.2 Tapping the emerging markets in developing regions

Chapter: 4 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY INDICATION

4.1 Market size and forecast by Indication

4.2.1 Market size and forecast by region
4.2.2 Rheumatoid Arthritis
4.2.3 Osteoarthritis
4.2.4 Ankylosing Spondylitis
4.2.5 Psoriatic Arthritis
4.2.6 Gout

4.3 Respiratory Diseases

4.3.1 Market size and forecast by region
4.3.2 Asthma
4.3.3 Chronic obstructive pulmonary disease (COPD)

4.4 Multiple Sclerosis

4.4.1 Market size and forecast by region

4.5 Psoriasis

4.5.1 Market size and forecast by region

4.6 Inflammatory Bowel Disease (IBD)

4.6.1 Market size and forecast by region
4.6.2 Crohn's Disease
4.6.3 Ulcerative Colitis

4.7 Other Inflammatory Diseases

4.7.1 Market size and forecast by region

Chapter: 5 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS

5.1 Anti-inflammatory Biologics

5.1.1 Key market trend
5.1.2 Market growth factors and opportunities
5.1.3 Market size and forecast by region

5.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.2.1 Key market trend
5.2.2 Market growth factors and opportunities
5.2.3 Market size and forecast by region

5.3 Corticosteroids

5.3.1 Key market trends
5.3.2 Market growth factors and opportunities
5.3.3 Market size and forecast by region

5.4 Other Anti-Inflammatory Drugs

Chapter: 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY

6.1 North America

6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.1.4 United States
6.1.5 Canada
6.1.6 Mexico

6.2 Europe

6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 United Kingdom
6.2.5 Germany
6.2.6 France
6.2.7 Rest of Europe

6.3 Asia Pacific

6.3.1 Key growth factors and opportunities
6.3.2 Market size and forecast
6.3.3 Japan
6.3.4 China
6.3.5 India
6.3.6 Rest of Asia Pacific

6.4 LAMEA

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Latin America
6.4.5 Middle East and Africa

Chapter: 7 COMPANY PROFILES

7.1 Pfizer Inc.

7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Business performance
7.1.4 Strategic moves and developments
7.1.5 SWOT analysis of Pfizer, Inc.

7.2 AbbVie Inc.

7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Business performance
7.2.4 Strategic Moves and Developments
7.2.5 SWOT analysis of AbbVie Inc.

7.3 Johnson & Johnson

7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Business performance
7.3.4 Strategic moves and developments
7.3.5 SWOT analysis & strategic conclusions

7.4 GlaxoSmithKline plc

7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Business performance
7.4.4 Strategic moves and developments
7.4.5 SWOT analysis & strategic conclusions

7.5 Merck & Co., Inc.

7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Business performance
7.5.4 Strategic moves and developments
7.5.5 SWOT analysis and strategic conclusions

7.6 Novartis AG

7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Business Performance
7.6.4 Strategic moves and developments
7.6.5 SWOT analysis and strategic conclusions

7.7 F. Hoffmann-La Roche AG

7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Business performance
7.7.4 Strategic moves and developments
7.7.5 SWOT analysis and strategic conclusions

7.8 Eli Lily and Company

7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Strategic moves and developments
7.8.5 SWOT analysis and strategic conclusions

7.9 AstraZeneca PLC.

7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Business performance
7.9.4 Strategic moves and developments
7.9.5 SWOT analysis and strategic conclusions

7.10 Amgen Inc.

7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Business performance
7.10.4 Strategic moves and developments
7.10.5 SWOT analysis and strategic conclusions